Northwest Biotherapeutics (NWBO) EBIT Margin (2010 - 2026)
Northwest Biotherapeutics (NWBO) posted quarterly EBIT Margin of 2206.48% for Q1 2026, up 240979.0% year-over-year from N/an in Q1 2025, and down 9.8% quarter-over-quarter from 2009.52% in Q4 2025.
Powered by 
Analysis
Northwest Biotherapeutics (NWBO) EBIT Margin (2010 - 2026) Analysis & Trends
Northwest Biotherapeutics' EBIT Margin history runs 17 years deep, the most recent figure standing at 2206.48% for Q1 2026.
- In Q1 2026, EBIT Margin rose 240979.0% year-over-year to 2206.48%; the TTM figure through Mar 2026 stood at 3574.01% (up 104751.0% YoY), while the FY2025 annual figure was 4347.9%, up 46455.0% from the prior year.
- EBIT Margin for Q1 2026 stood at 2206.48%, down from 2009.52% in the prior quarter.
- The five-year high for EBIT Margin was 1473.18% in Q1 2023, with the low at 11281.68% in Q2 2025.
- The 5-year median for EBIT Margin is 4145.94% (2024), against an average of 4795.89%.
- Peak annual rise in EBIT Margin reached 599870 bps in 2025, while the deepest fall reached 785737 bps in 2025.
- Northwest Biotherapeutics' EBIT Margin stood at 3044.89% in 2022, then dropped by 12 bps to 3402.7% in 2023, then slumped by 135 bps to 8008.23% in 2024, then surged by 75 bps to 2009.52% in 2025, then declined by 10 bps to 2206.48% in 2026.
- Business Quant data shows NWBO's EBIT Margin at 2206.48% in Q1 2026, 2009.52% in Q4 2025, and 7160.0% in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -562.07% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 19.06% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 17.93% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 19.75% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -0.36% |
| 10 | Northwest Biotherapeutics | 278.23 Mn | 277.63 Mn | - | -1,438.04% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -1,438.04% |
| Mar 31, 2026 | -2,206.48% |
| Dec 31, 2025 | -2,009.52% |
| Sep 30, 2025 | -7,160.00% |
| Jun 30, 2025 | -11,281.68% |
| Mar 31, 2025 | -4,616.27% |
| Dec 31, 2024 | -8,008.23% |
| Sep 30, 2024 | -4,145.94% |
| Jun 30, 2024 | -3,424.31% |
| Mar 31, 2024 | -5,543.66% |
| Dec 31, 2023 | -3,402.70% |
| Sep 30, 2023 | -3,405.17% |
| Jun 30, 2023 | -6,754.73% |
| Mar 31, 2023 | -1,473.18% |
| Dec 31, 2022 | -3,044.89% |
| Sep 30, 2022 | -7,581.55% |
| Jun 30, 2022 | -4,423.27% |
| Mar 31, 2022 | -3,048.64% |
| Sep 30, 2021 | -2,871.14% |
| Jun 30, 2021 | -2,982.45% |